RU2425054C2 - Антитела против il2 - Google Patents

Антитела против il2 Download PDF

Info

Publication number
RU2425054C2
RU2425054C2 RU2007143996/10A RU2007143996A RU2425054C2 RU 2425054 C2 RU2425054 C2 RU 2425054C2 RU 2007143996/10 A RU2007143996/10 A RU 2007143996/10A RU 2007143996 A RU2007143996 A RU 2007143996A RU 2425054 C2 RU2425054 C2 RU 2425054C2
Authority
RU
Russia
Prior art keywords
amino acid
acid sequence
human
monoclonal antibody
seq
Prior art date
Application number
RU2007143996/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2007143996A (ru
Inventor
Патрик БОЕРЛЕ (DE)
Патрик БОЕРЛЕ
Джон ЛУМСДЕН (DE)
Джон ЛУМСДЕН
Штефан ПФЛАНЦ (DE)
Штефан ПФЛАНЦ
Тобиас РАУМ (DE)
Тобиас Раум
Йорг ФОЛЬКЛАНД (DE)
Йорг ФОЛЬКЛАНД
Original Assignee
Микромет Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Микромет Аг filed Critical Микромет Аг
Publication of RU2007143996A publication Critical patent/RU2007143996A/ru
Application granted granted Critical
Publication of RU2425054C2 publication Critical patent/RU2425054C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
RU2007143996/10A 2005-06-01 2006-05-31 Антитела против il2 RU2425054C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05011845 2005-06-01
EP05011845.4 2005-06-01

Publications (2)

Publication Number Publication Date
RU2007143996A RU2007143996A (ru) 2009-07-20
RU2425054C2 true RU2425054C2 (ru) 2011-07-27

Family

ID=37025008

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007143996/10A RU2425054C2 (ru) 2005-06-01 2006-05-31 Антитела против il2

Country Status (15)

Country Link
US (1) US7964707B2 (cg-RX-API-DMAC7.html)
EP (1) EP1888644A1 (cg-RX-API-DMAC7.html)
JP (1) JP5414271B2 (cg-RX-API-DMAC7.html)
KR (1) KR101340559B1 (cg-RX-API-DMAC7.html)
CN (1) CN101189265B (cg-RX-API-DMAC7.html)
AU (1) AU2006254333B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610912A2 (cg-RX-API-DMAC7.html)
CA (1) CA2609234C (cg-RX-API-DMAC7.html)
IL (1) IL187316A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007014565A (cg-RX-API-DMAC7.html)
NO (1) NO20076568L (cg-RX-API-DMAC7.html)
NZ (1) NZ563213A (cg-RX-API-DMAC7.html)
RU (1) RU2425054C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006128690A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200709456B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745451C1 (ru) * 2017-05-25 2021-03-25 Инститьют Фор Бейсик Сайенс Антитела к человеческому интерлейкину-2 и их применение
RU2832154C2 (ru) * 2019-03-18 2024-12-19 Бионтех Сел Энд Джин Терепиз Гмбх Варианты рецептора интерлейкина-2 (il2r) и интерлейкина-2 (il2) для специфической активации иммунных эффекторных клеток
US12595292B2 (en) 2019-03-18 2026-04-07 Biontech Cell & Gene Therapies Gmbh Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009704A (es) * 2009-03-16 2011-09-28 Cephalon Australia Pty Ltd Anticuerpos humanizados con actividad anti-tumor.
CA2778552A1 (en) * 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes
AU2013243574B2 (en) * 2012-04-03 2017-12-07 Novelmed Therapeutics, Inc Humanized and chimeric anti-factor C3 antibodies and uses thereof
SG10201805706XA (en) 2013-12-12 2018-08-30 Umc Utrecht Holding Bv Immunoglobulin-like molecules directed against fibronectin-eda
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
CA2954476C (en) 2014-07-10 2023-09-19 Novartis Ag Immune-stimulating monoclonal antibodies against human interleukin-2
EP3365369A1 (en) 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof
JP6993699B2 (ja) 2016-01-11 2022-02-03 ウニヴェルズィテート・ツューリヒ ヒトインターロイキン-2に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
JP7120989B2 (ja) 2016-07-06 2022-08-17 セルジーン コーポレイション 低免疫原性を有する抗体及びその使用
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
WO2019045075A1 (ja) 2017-08-31 2019-03-07 田辺三菱製薬株式会社 Il-33アンタゴニストを含む子宮内膜症治療剤
JP7245358B2 (ja) 2019-06-10 2023-03-23 山東博安生物技術股▲ふん▼有限公司 抗cd25抗体及びその適用
WO2022207521A1 (en) 2021-03-30 2022-10-06 F. Hoffmann-La Roche Ag Protease-activated polypeptides
CN113248610B (zh) * 2021-05-14 2022-08-16 厦门柏慈生物科技有限公司 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途
CN119948048A (zh) 2022-09-29 2025-05-06 豪夫迈·罗氏有限公司 蛋白酶活化的多肽
CN115850471B (zh) * 2022-10-13 2026-04-07 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用
CN119661706B (zh) * 2024-01-31 2025-11-28 康立泰生物医药(青岛)有限公司 一种抗人白介素2抗体及其应用
CN118515762B (zh) * 2024-07-23 2024-11-01 北京百普赛斯生物科技股份有限公司 特异性结合il-2的抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197993C2 (ru) * 1996-12-11 2003-02-10 Авентис Фарма Дойчланд Гмбх Самоусиливающиеся фармакологически контролируемые экспрессионные системы
RU2004114882A (ru) * 2001-11-14 2005-04-20 Сентокор, Инк. (Us) Антитела против il-6, композиции, способы и применение

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001274939A1 (en) 2000-05-24 2001-12-03 Smith Kline Beecham Corporation Sialoadhesin factor-3 antibodies
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU2003295471B2 (en) * 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25
ES2398394T3 (es) * 2003-08-13 2013-03-15 Novartis Vaccines And Diagnostics, Inc. Reactivos peptídicos específicos de prión

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197993C2 (ru) * 1996-12-11 2003-02-10 Авентис Фарма Дойчланд Гмбх Самоусиливающиеся фармакологически контролируемые экспрессионные системы
RU2004114882A (ru) * 2001-11-14 2005-04-20 Сентокор, Инк. (Us) Антитела против il-6, композиции, способы и применение

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745451C1 (ru) * 2017-05-25 2021-03-25 Инститьют Фор Бейсик Сайенс Антитела к человеческому интерлейкину-2 и их применение
RU2832154C2 (ru) * 2019-03-18 2024-12-19 Бионтех Сел Энд Джин Терепиз Гмбх Варианты рецептора интерлейкина-2 (il2r) и интерлейкина-2 (il2) для специфической активации иммунных эффекторных клеток
US12595292B2 (en) 2019-03-18 2026-04-07 Biontech Cell & Gene Therapies Gmbh Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells

Also Published As

Publication number Publication date
CA2609234A1 (en) 2006-12-07
US7964707B2 (en) 2011-06-21
AU2006254333A1 (en) 2006-12-07
CN101189265A (zh) 2008-05-28
KR20080032046A (ko) 2008-04-14
IL187316A0 (en) 2008-04-13
NO20076568L (no) 2008-02-19
MX2007014565A (es) 2008-02-11
BRPI0610912A2 (pt) 2008-12-02
EP1888644A1 (en) 2008-02-20
CN101189265B (zh) 2012-07-04
KR101340559B1 (ko) 2013-12-11
US20080317746A1 (en) 2008-12-25
JP5414271B2 (ja) 2014-02-12
NZ563213A (en) 2009-07-31
JP2008542321A (ja) 2008-11-27
WO2006128690A1 (en) 2006-12-07
RU2007143996A (ru) 2009-07-20
AU2006254333B2 (en) 2011-02-17
CA2609234C (en) 2014-04-22
ZA200709456B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
US12269896B2 (en) Antibodies specific for GUCY2c and uses thereof
US7964707B2 (en) Anti-IL2 antibodies
RU2739610C1 (ru) Антитело против PD-1 и его применение
US20160194402A1 (en) Cd70-binding peptides and method, process and use relating thereto
RU2687209C1 (ru) Собачьи антитела с модифицированными последовательностями ch2-ch3
KR101859857B1 (ko) Il-21 항체
US20230192861A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
CN103038254A (zh) 拮抗性抗il-7受体抗体及方法
AU2020390288A1 (en) Antibodies to CD3 and BCMA, and bispecific binding proteins made therefrom
JP7843824B2 (ja) 抗体および使用方法
EP4610275A2 (en) Anti-pd-1 antibodies and fusion proteins
JP2022529269A (ja) ヒト化抗pd-l1抗体
KR20160125965A (ko) 신규 인간 tlr2 및 인간 tlr4에 결합하는 이중 특이적 항체
WO2022153997A1 (ja) ActRIIA、ActRIIB及びFn14に結合する多重特異性抗体
KR20200135331A (ko) 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도
HK40060091A (en) Antibodies specific for gucy2c and uses thereof

Legal Events

Date Code Title Description
PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20131127

PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190601